Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 19/20 | 0.57 |
| ▸ | RAF1 | P04049 | 1/20 | 0.56 |
| ▸ | KDR | P35968 | 7/20 | 0.53 |
| ▸ | LCK | P06239 | 1/20 | 0.49 |
| ▸ | FYN | P06241 | 1/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.49 |
| ▸ | KIT | P10721 | 1/20 | 0.49 |
| ▸ | SRC | P12931 | 1/20 | 0.49 |
| ▸ | FLT1 | P17948 | 1/20 | 0.49 |
| ▸ | FLT4 | P35916 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30313590 | 1.00 | BRAF (0.57) | BRAFRAF1KDRLCKFYN | |
| SCHEMBL24007052 | 0.87 | BRAF (0.68) | BRAFRAF1KDRLCKFYN | |
| SCHEMBL4325129 | 0.85 | BRAF (0.78) | BRAFRAF1KDRLCKFYN | |
| SCHEMBL24374953 | 0.85 | BRAF (0.52) | BRAFRAF1KDRLCKFYN | |
| SCHEMBL23795595 | 0.84 | ABL1 (0.54) | BRAFRAF1KDRLCKFYN | |
| SCHEMBL29845682 | 0.83 | BRAF (0.51) | BRAFRAF1KDR | |
| SCHEMBL23166490 | 0.83 | BRAF (0.51) | BRAFRAF1KDR | |
| SCHEMBL25358410 | 0.81 | BRAF (0.47) | BRAFRAF1KDRLCKFYN | |
| SCHEMBL24007068 | 0.81 | BRAF (0.47) | BRAFRAF1KDRLCKFYN | |
| SCHEMBL24815081 | 0.80 | BRAF (0.49) | BRAFRAF1KDRLCKFYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265075-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. | 2023-08-24 | — | — | US | disclosed |
| US-11691963-B2 | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors | AJAX THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| CN-115996917-A | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors | 艾捷斯治疗公司 | 2023-04-21 | — | — | CN | disclosed |
| US-20220411403-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. | 2022-12-29 | — | — | US | disclosed |
| WO-2021226261-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. (US) | 2021-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411403-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | JAK2, JAK3, STAT5B | BRAF 733/4885RAF1 2140/4885KDR 349/4885 |
| US-20230265075-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | JAK2, JAK3, STAT5B | BRAF 733/4885RAF1 2140/4885KDR 349/4885 |
| US-11691963-B2 | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors | JAK2, JAK3, STAT5B | BRAF 733/4885RAF1 2140/4885KDR 349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.